Daily Newsletter

31 August 2023

Share with colleague
Subscribe

Daily Newsletter

31 August 2023

Share with colleague
Subscribe

Spotlight

Genexine’s GX-H9 therapy trial meets primary endpoint

Patients received weekly injection of eftansomatropin alfa and daily injections of Norditropin.

Latest news

Urotronic reveals follow-up data for its Optilume BPH catheter system

The drug-device system causes mechanical dilation and delivers paclitaxel to treat urinary tract symptoms in benign prostatic hyperplasia patients.

31 August 2023

SparingVision announces safety data from first cohort of RP therapy trial

The Data Safety Monitoring Board reviewed the safety data and recommended dosing the second cohort with medium dose.

31 August 2023

Signal: Apellis sheds staff weight plus R&D in a bid to restructure company

Apellis aims to attain long-term success and focus on star candidate Syfovre by trimming staff and cutting costs.

31 August 2023

Codagenix pursues RSV vaccine development amid unexpected challenges

Codagenix faces a late 2024 data readout following enrollment challenges in its paediatric RSV vaccine Phase I study.

31 August 2023

Alpine initiates second cohort dosing in trial to treat glomerulonephritis

No serious severe adverse events and instances of hypersensitivity were observed with repeat dosing of povetacicept.

31 August 2023

Alzamend targets Phase IIa trial for bipolar treatment candidate

The company is aiming to overcome associated toxicities with lithium treatment by decreasing the daily dose needed to elevate brain drug levels.

31 August 2023

AIC concludes patient enrolment in F14 trial to relieve knee surgery pain

Top-line data from the study is anticipated in the first quarter of next year.

31 August 2023

mRNA vaccines represent >40% of the authorized/approved COVID-19 vaccines and boosters in the 7 major pharmaceutical markets

There are currently 13 authorized/approved COVID-19 vaccines in the 7 major pharma markets. Currently, vaccine developers plan to launch updated boosters prior to the upcoming 2023 fall season to target the latest dominant strain, Omicron XBB.1.5. Per GlobalData analysis, mRNA vaccines will likely continue to dominate the market, though as the pandemic winds down, the global COVID-19 vaccines market is expected to decline.